Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma.

ABSTRACT: In patients with Kaposi's sarcoma (KS), the therapeutic goal is to achieve a durable remission in the size and number of skin and visceral lesions. Although most patients show tumor regression in response to standard systemic chemotherapy regimens, alternative systemic treatments are needed for patients who develop refractory KS. Anti-angiogenic therapies represent attractive therapeutic targets in this context, due to the central role of angiogenesis in KS pathogenesis. Pomalidomide, which exhibits such anti-angiogenic activity through inhibition of VEGF, currently constitutes the most promising agent of this class and has been recently approved by the FDA. In addition, immune checkpoint blockade also represents an interesting alternative therapeutic approach through the restoration of im

SUBMITTER: Valantin MA 

PROVIDER: S-EPMC8833559 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature